New hope for advanced cancer patients: SKB103 trial begins
NCT ID NCT07459998
First seen Mar 12, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This study tests a new drug, SKB103, in about 277 adults aged 18-75 with advanced solid tumors that have not responded to standard treatments or for which no standard therapy exists. The goal is to find a safe dose and see if the drug can shrink tumors. The study is currently recruiting participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai East Hospital, Tongj.University
RECRUITINGShanghai, Shanghai Municipality, 200123, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.